Eli Lilly's Zepbound Shows Promise in Reducing Heart Failure Risks

Clinical trial reveals significant cardiovascular benefits for the weight-loss drug, potentially expanding its use and coverage.

Zepbound cuts risk of heart failure-related complications by 38% compared to placebo in a two-year study.
The drug also alleviates symptoms like shortness of breath, fatigue, and irregular heartbeat.
Participants experienced an average weight loss of 15.7% during the trial.
Eli Lilly plans to submit the trial results to the FDA and other regulators later this year.
The company anticipates the end of the current Zepbound shortage 'very soon,' according to the CEO.